All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, March 21, 2023
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

In the clinic for Dec. 15, 2022

Dec. 15, 2022
No Comments
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Actinogen, Alto, Avidity, Catalym, Dermaliq, Ellipses, Epicentrx, Imaginab, Geneos, Genprex, Icosavax, Irlab, Kymera, Moonlake, Oxurion, Passage, Precision, Quoin, Recbio, Splisense, Tracon, Ultimovacs.
Read More

Other news to note for Dec. 15, 2022

Dec. 15, 2022
No Comments
Additional early-stage research and drug discovery news in brief, from: Dyadic, Nuvalent.
Read More
Colorized transmission electron micrograph of rabies virus.
Infection

Everest achieves preclinical proof-of-concept milestone for its mRNA rabies vaccine

Dec. 15, 2022
No Comments
Everest Medicines Ltd. has achieved a preclinical proof-of-concept milestone for its mRNA rabies vaccine program. This new vaccine candidate for rabies post-exposure prophylaxis was developed in partnership with Providence Therapeutics Holdings Inc. utilizing a clinically validated mRNA technology platform.
Read More

Regulatory actions for Dec. 14, 2022

Dec. 14, 2022
No Comments
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Bittium, Quantumdx.
Read More

Other news to note for Dec. 14, 2022

Dec. 14, 2022
No Comments
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbvie, Bioxytran, Eva, Exicure, Harrow Ipsen, Lilly.
Read More
Red wooden approved stamp

Shionogi scores emergency approval for Japan’s first domestic COVID-19 oral antiviral

Dec. 13, 2022
By Tamra Sami
No Comments
Shionogi & Co. Ltd.’s orally administered COVID-19 antiviral, 3CL protease inhibitor Xocova (ensitrelvir/S-217622), scored emergency regulatory approval from Japan’s Ministry of Health, Labor and Welfare for SARS-CoV-2 infection, and the Japanese government has agreed to purchase 1 million courses of Xocova for domestic supply of the antiviral.
Read More

Regulatory actions for Dec. 13, 2022

Dec. 13, 2022
No Comments
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Brainstorm, Evergreen, Galera, Ideaya, Janssen, Medivir, Pfizer, Recce, Sobi, Vertex.
Read More

Other news to note for Dec. 13, 2022

Dec. 13, 2022
No Comments
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbvie, Asieris, Astrazeneca, Biosion, Calidi, Calliditas, Glycotope, Immunogen, Lantern, Sosei, Therabest, Viatris, Zyversa.
Read More
Infection

Japanese researchers patent new viral 3CLpro inhibitors

Dec. 13, 2022
No Comments
The National Center for Global Health and Medicine (NCGM) and Tokyo Medical and Dental University have divulged 3C-like protease (3CLpro) (SARS-CoV-2) inhibitors reported to be useful for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections (COVID-19).
Read More

Regulatory actions for Dec. 12, 2022

Dec. 12, 2022
No Comments
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Alnylam, Antengene, Biogen, Braeburn, Janssen, Pfizer, Recce.
Read More
Previous 1 2 … 11 12 13 14 15 16 17 18 19 … 502 503 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 20, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for March 20, 2022.
  • Woman with headache

    Nasal spray Zavzpret cleared, Pfizer showing ‘growth on every measure’ in migraine

    BioWorld
    Pricing won’t be known until later for Pfizer Inc.’s Zavzpret (zavegepant), which became the first and only calcitonin gene-related peptide receptor antagonist...
  • Lungs

    Affibody in $637M respiratory disease deal with Chiesi

    BioWorld
    Chiesi Farmaceutici SpA has agreed to pay Affibody AB up to $214 million in a collaboration and licensing agreement to develop an inhaled treatment for...
  • Women handshake with virology graphics

    Modex codex may read out new story in EBV with Merck vaccine pact worth $922M-plus

    BioWorld
    Another step forward in the quest for an Epstein-Barr virus (EBV) vaccine took the form of Merck & Co. Inc.’s deal with Modex Therapeutics Inc., owned by Opko...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing